Level Biotechnology Total Current Liabilities

As of the most recent data (June 2026), 3118.TWO shows a total current liabilities of $250M. That compares with $300M in the prior-year period — down 17.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 3118.TWO's total current liabilities is now $250M (was $300M) — a 17.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Level Biotechnology is outperforming or lagging.

Tracking 3118.TWO's total current liabilities over time shows whether Level Biotechnology is scaling, shrinking, or reshaping that part of the business. The current reading is $250M That compares with $300M in the prior-year period — down 17.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Level Biotechnology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $250M) with ownership activity and broader fundamentals.

Level Biotechnology's total current liabilities is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.